Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.24 USD | +2.92% | +8.53% | +16.92% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.92% | 5.34B | |
+2.70% | 108B | |
+9.93% | 105B | |
+1.57% | 23.46B | |
-12.06% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.70% | 17.19B | |
+6.01% | 13.99B | |
+35.90% | 12.53B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing